Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RNA-based therapy
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : ARCH Venture Partners
Deal Size : $270.0 million
Deal Type : Series A Financing
Details : The financing will be used to support the advancement of an Industry-leading, comprehensive platform of RNA technologies and a first-in-class portfolio of programmable RNA-based therapies.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 26, 2023
Lead Product(s) : RNA-based therapy
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : ARCH Venture Partners
Deal Size : $270.0 million
Deal Type : Series A Financing
Lead Product(s) : RNA-based Medicine
Therapeutic Area : Immunology
Study Phase : Undisclosed
Recipient : Beam Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of its launch, Orbital and Beam Therapeutics have entered into a license and research collaboration under which Orbital and Beam have each granted the other access to respective RNA technology and non-viral delivery technology.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 07, 2022
Lead Product(s) : RNA-based Medicine
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Recipient : Beam Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : RNA-based Vaccine
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Beam Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RNA-based medicines represent fast-growing and disruptive class of therapeutics for a breadth of disease areas. First-generation RNA treatments successfully overcame multiple hurdles, such as the rapid degradation of exogenous RNA, delivery of RNA.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 07, 2022
Lead Product(s) : RNA-based Vaccine
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Beam Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?